Shanghai Henlius Biotech (HKG:2696) dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.
The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.